[Liposomes as non-viral carriers for genetic drugs]

Area of Science:

• Oncology
• Gene Therapy
• Nanotechnology

Background:

• Cancer therapy methods are rapidly evolving, necessitating novel and more effective treatment strategies.
• Antisense gene therapy presents a promising approach for neoplastic diseases due to its potential for low toxicity and targeting molecular causes.
• Effective in vivo delivery of therapeutic oligonucleotides to target cells is crucial for gene therapy success.

Purpose of the Study:

• To review new generations of non-viral drug carriers for targeted gene therapy.
• To focus on immunoliposomes as a potential carrier system for in vivo gene therapy applications.
• To highlight advancements in cancer treatment strategies utilizing gene therapy.

Main Methods:

• Review of current literature on non-viral drug carriers in gene therapy.
• Focus on immunoliposomes and their characteristics for targeted delivery.
• Analysis of the application of these carriers in cancer treatment.

Main Results:

• Non-viral drug carriers are increasingly utilized in targeted gene therapy systems.
• Immunoliposomes represent a new generation of non-viral carriers with potential applications in targeted gene therapy.
• These advanced carriers aim to improve the efficacy and safety of gene therapy for cancer.

Conclusions:

• Non-viral carriers, particularly immunoliposomes, are vital for the advancement of targeted antisense gene therapy.
• The development of effective delivery systems is key to realizing the breakthrough potential of gene therapy in cancer treatment.
• Further research into immunoliposomes can enhance their application in clinical oncology.